Effect of stabilized iodized oil emulsion on experimentally induced hepatocellular carcinoma in rats

Journal of Vascular and Interventional Radiology

Volumn 16, Issue 6, 2005, Pages 841-848

  Garin, Etienne ^a,e   Denizot, Benoit ^b,c   Roux, Jérôme ^c   Noiret, Nicolas ^d   Lepareur, Nicolas ^d   Moreau, Myriam ^b   Mesba, Abiba ^f   Laurent, Jean François ^f   Herry, Jean Yves ^a   Bourguet, Patrick ^a   Benoit, Jean Pierre ^b   Lejeune, Jean Jacques ^b  

^a UPRES EA 3890/Nuclear Medicine Service   (France)

^b INSERM   (France)

^c UNIVERSITÉ D'ANGERS   (France)

^d UNIV RENNES   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGENATED CASTOR OIL; IODINATED POPPYSEED OIL; MACROGOL; TECHNETIUM SULFUR COLLOID TC 99M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; EMULSION; EX VIVO STUDY; FEMALE; HEPATIC ARTERY; HISTOPATHOLOGY; HYDROPHILICITY; ISOTOPE LABELING; LIPOPHILICITY; LIVER CELL CARCINOMA; LUNG FUNCTION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; VISCOSITY;

EID: 20544467261     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000156192.89569.0C     Document Type: Article

References (38)

1. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787.
2. Trinchet JC, Beaugrand M. Augmentation de l'incidence du carcinome hépatocellulaire dans les pays occidentaux. Gastroenterol Clin Biol 1999; 23: 1286-1288.
3. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1974-94. Lancet 1997; 350:1142-1143.
4. Deuffic S, Poynard T. Trends in primary liver cancer. Lancet 1998; 351:214-215.
5. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32(suppl 1):225-237.
6. Badvie S. Hepatocellular carcinoma. Postgrad Med J 2000; 76:4-11.
7. Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb 2002; 47:389-399.
8. Garin E, Bourguet P. Use of labelled lipiodol in the treatment of hepatic tumors. In: Ell PJ, Gambhir SS, eds. Nuclear medicine in clinical diagnosis and treatment, 3rd ed. Edinburgh, UK: Elsevier, 2004;473-483.
9. 131I-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-1161.
10. Lau WY, Leung TWT, Ho SKW, et al. Adjuvant intra-arterial iodine-131-labelled Lipiodol for respectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999; 353: 797-801.
11. 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001; 28:197-204.
12. Sundram FX, Jeong JM, Zanzonico P, et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-centre phase 1 study. World J Nucl Med 2002; 1:5-11.
13. Boschi A, Uccelli L, Duatti A, et al. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Comm 2004; 25:691-699.
14. 188Re-SSS lipiodol following injection into hepatic artery of healthy pig. Eur J Nucl Med Mol Imaging 2004; 31:542-546.
15. 188Re-SSS Lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nucl Med Comm 2004; 25:1007-1013.
16. De Baere T, Zhang X, Aubert B, et al. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology 1996; 201:731-735.
17. Yi SW, Kim YH, Kwon IC, et al. Stable lipiodolize emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolisation. J Control Release 1998; 50:135-143.
18. Hamuro M, Nakamura K, Sakai Y, et al. New oily agents for targeting chemoembolisation for hepatocellular carcinoma. Cardiovasc Intervent Radiol 1999; 22:130-134.
19. 99mTc- labelled lipiodol: biodistribution following injection into hepatic artery of healthy pig. Nucl Med Comm 2004; 25:291-297.
20. 188Re in the treatment of hepatic tumor. J Radioanal Nucl Chem 2004; 261(1):189-193.
21. Novikoff AB. A transplantable liver tumor induced by 4-dimethylamino- azobenzene. Cancer Res 1957; 17:1010-1027.
22. Brans B, Van Laere K, Gemmel F, et al. Combined iodine-131 Lipiodol therapy with low-dose cisplatin as radiosensitiser: preliminary study results in hepatocellular carcinoma. Eur J Nucl Med 2002; 29:928-932.
23. Raoul JL, Boucher E, Rolland Y, Garin E. Association of CDDP and intra-arterial injection of 131I-Lipiodol (lip 131I) in the treatment of hepatocellular carcinoma (HCC): results of a phase II trial. J Clin Oncol 2002; 21(suppl):563.
24. Kaplan HS, Bagshaw MA. Radiation hepatitis: possible prevention by combined isotopic and external radiation therapy. Radiology 1968; 91:1214-1220.
25. Kraut JW, Kaplan HS, Bagshaw MA. Combined fractionated isotopic and external irradiation of the liver in Hodgkin's disease. Cancer 1972; 30:39-46.
26. O'Donoghue JA, Bardiès M, Wheldon TE. Relationship between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-1909.
27. Burton MA, Gray BN, Self GW, Heggie JC, Towensend PS. Manipulation of experimental rat and rabbit liver tumor blood flow with angiotensin II. Cancer Res 1985; 45:5390-5393.
28. Burton MA, Gray BN, Coletti A. Effect of angiotensin II on blood flow in the transplanted sheep squamous cell carcinoma. Eur J Cancer Clin Oncol 1988; 24:1373-1376.
29. Raoul JL, Bourguet P, Bretagne JF, et al. Hepatic artery injection of I-131-labeled Lipiodol. Part 1: biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168:541-545.
30. Nakajo M, Kobayashi H, Shimabukuro K, et al. Biodistribution and in vivo kinetics of iodine 131 Lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988; 29: 1066-1077.
31. Kan Z, Ivancev K, Hägerstrand I, Chuang VP, Lunderquist A. In vivo microscopy of the liver after injection of Lipiodol into the hepatic artery and portal vein in the rat. Acta Radiol 1989; 30:419-425.
32. Park C, Choi SI, Kim H, Yoo HS, Lee YB. Distribution of Lipiodol in hepatocellular carcinoma. Liver 1990; 10:72-78.
33. Chou FI, Fang KC, Chung C, et al. Lipiodol uptake and retension by human hepatoma cells. Nucl Med Biol 1995; 22:379-386.
34. Preketes AP, Boyd S, Cooper D, et al. Pulmonary toxicity following Lipiodol I-131 treatment for liver tumors. Reg Cancer Treat 1996; 9:21-26.
35. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787.
36. Raoul JL, Bretagne JF, Caucanas JP, et al. Internal radiation therapy for hepatocellular carcinoma: results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. Cancer 1992; 69:346-352.
37. Brans B, De Winter F, Defreyne L, et al. The anti-tumoral activity of neoadjuvant intra-arterial 131I-Lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 2001; 4:333-338.
38. Tajima T, Honda H, Kuroiwa T, et al. Pulmonary complications after hepatic arterial chemoembolization infusion via the inferior phrenic artery for primary liver cancer. J Vasc Int Radiol 2002; 13:893-900.